AutoCAT: automated cancer-associated TCRs discovery from TCR-seq data

Bioinformatics. 2022 Jan 3;38(2):589-591. doi: 10.1093/bioinformatics/btab661.

Abstract

Summary: T cells participate directly in the body's immune response to cancer, allowing immunotherapy treatments to effectively recognize and target cancer cells. We previously developed DeepCAT to demonstrate that T cells serve as a biomarker of immune response in cancer patients and can be utilized as a diagnostic tool to differentiate healthy and cancer patient samples. However, DeepCAT's reliance on tumor bulk RNA-seq samples as training data limited its further performance improvement. Here, we benchmarked a new approach, AutoCAT, to predict tumor-associated TCRs from targeted TCR-seq data as a new form of input for DeepCAT, and observed the same level of predictive accuracy.

Availability and implementation: Source code is freely available at https://github.com/cew88/AutoCAT, and data is available at 10.5281/zenodo.5176884.

Supplementary information: Supplementary data are available at Bioinformatics online.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Immunotherapy
  • Neoplasms* / genetics
  • RNA-Seq
  • Receptors, Antigen, T-Cell* / genetics
  • Software
  • T-Lymphocytes

Substances

  • Receptors, Antigen, T-Cell